1.
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424
(2018).
2.
Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and
major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
3.
National Cancer Institute. Cancer Stat Facts: Cancer of Any Site.
https://seer.cancer.gov/statfacts/html/all.html
4.
Bronson, R. Variation in age at death of dogs of different sexes and breeds. Am J Vet
Res . 43, 2057–2059 (1982).
5.
Merlo, D. F. et al. Cancer incidence in pet dogs: Findings of the animal tumor
registry of Genoa, Italy. J. Vet. Intern. Med. 22, 976–984 (2008).
6.
Baioni, E. et al. Estimating canine cancer incidence: Findings from a populationbased tumour registry in northwestern Italy. BMC Vet. Res. 13, 203 (2017).
7.
Vascellari, M. et al. Incidence of mammary tumors in the canine population living in
the Veneto region (Northeastern Italy): Risk factors and similarities to human
breast cancer. Prev. Vet. Med. 126, 183–189 (2016).
8.
Chen, D. S. & Mellman, I. Oncology meets immunology: The cancer-immunity cycle.
88
Immunity 39, 1–10 (2013).
9.
Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic
Melanoma. N. Engl. J. Med. 363, 711–723 (2010).
10.
Robert, C. et al.
Nivolumab in Previously Untreated Melanoma without BRAF
Mutation . N. Engl. J. Med. 372, 320–330 (2015).
11.
Robert, C. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N.
Engl. J. Med. 372, 2521–2532 (2015).
12.
Couzin-Frankel, J. Cancer immunotherapy. Science 342, 1432–1433 (2013).
13.
Kaiser, J. & Couzin-Frankel, J. Cancer immunotherapy sweeps Nobel for medicine:
Prize goes to discoveries that unleash immune system. Science 362, 13 (2018).
14.
Hegde, P. S. & Chen, D. S. Top 10 Challenges in Cancer Immunotherapy. Immunity
52, 17–35 (2020).
15.
Bujak, J. K., Pingwara, R., Nelson, M. H. & Majchrzak, K. Adoptive cell transfer:
New perspective treatment in veterinary oncology. Acta Vet Scand. 60, 60 (2018).
16.
Mule, J., Shu, S., Schwarz, S. & Rosenberg, S. Adoptive immunotherapy of
established pulmonary metastases with LAK cells and recombinant interleukin-2.
Science 225, 1487-1489 (1984).
17.
Eberlein, T. J., Rosenstein, M. & Rosenberg, S. A regression a disseminated
89
syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin
2. J. Exp. Med. 156, 385–397 (1982).
18.
Grimm, E. A., Mazumder, A., Zhang, H. Z. & Rosenberg, S. A. Lymphokine-activated
killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by
interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp.
Med. 155, 1823-1841 (1982).
19.
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive
cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer. 8,
299–308 (2008).
20.
Rosenberg, S. A. & Lotze, M. T. Cancer Immunotherapy Using Interleukin-2 and
Interleukin-2-Activated Lymphocytes. Annu. Rev. Immunol. 4, 681-709 (1986).
21.
Hoshino, Y., Takagi, S., Osaki, T., Okumura, M. & Fujinaga, T. Phenotypic analysis
and effects of sequential administration of activated canine lymphocytes on healthy
beagles. J. Vet. Med. Sci. 70, 581–588 (2008).
22.
Helfand, S. C., Soergel, S. A., Modiano, J. F., Hank, J. A. & Sondel, P. M. Induction
of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose
human recombinant interleukin-2 in vitro. Cancer Biother. 9, 237–244 (1994).
23.
Itoh, H. et al. Bulk cultures of canine peripheral blood lymphocytes with solid phase
90
Anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy. J. Vet.
Med. Sci. 65, 329-333 (2003).
24.
Mie, K., Shimada, T., Akiyoshi, H., Hayashi, A. & Ohashi, F. Change in peripheral
blood lymphocyte count in dogs following adoptive immunotherapy using
lymphokine-activated T killer cells combined with palliative tumor resection. Vet.
Immunol. Immunopathol. 177, 58–63 (2016).
25.
Piras, F. et al. The predictive value of CD8, CD4, CD68 and human leukocyte
antigen-D-related cells in the prognosis of cutaneous malignant melanoma with
vertical growth phase. Cancer 104, 1246–1254 (2005).
26.
Van Houdt, I. S. et al. Favorable outcome in clinically stage II melanoma patients is
associated with the presence of activated tumor infiltrating T-lymphocytes and
preserved MHC class I antigen expression. Int. J. Cancer 123, 609–615 (2008).
27.
Wang, K., Xu, J., Zhang, T. & Xue, D. Tumor-infiltrating lymphocytes in breast
cancer predict the response to chemotherapy and survival outcome: A meta-analysis.
Oncotarget 7, 44288-44298 (2016).
28.
Mahmoud, S. M. A. et al. Tumor-infiltrating CD8+ lymphocytes predict clinical
outcome in breast cancer. J. Clin. Oncol. 29, 1949–1955 (2011).
29.
Mei, Z. et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer:
91
Systematic review and meta-analysis. Br. J. Cancer 110, 1595–1605 (2014).
30.
Dudley, M. E. et al. Adoptive Cell Transfer Therapy Following Non-Myeloablative
but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory
Metastatic Melanoma. J. Clin. Oncol. 23, 2346-2357 (2005).
31.
Dudley ME et al. Cancer Regression and Autoimmunity in Patients After Clonal
Repopulation with Antitumor Lymphocytes. Science 298, 850-854 (2002).
32.
Rosenberg, S. A. et al. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in
the Immunotherapy of Patients with Metastatic Melanoma. N. Engl. J. Med. 319,
1676-1680 (1988).
33.
Besser, M. J. et al. Clinical responses in a phase II study using adoptive transfer of
short-term cultured tumor infiltration lymphocytes in metastatic melanoma
patients. Clin. Cancer Res. 16, 2646–2655 (2010).
34.
Pilon-Thomas, S. et al. Efficacy of adoptive cell transfer of tumor-infiltrating
lymphocytes after lymphopenia induction for metastatic melanoma. J. Immunother.
35, 615–620 (2012).
35.
Nicholls, P. K. et al. Regression of canine oral papillomas is associated with
infiltration of CDA+ and CD8+ lymphocytes. Virology 283, 31–39 (2001).
36.
Estrela-Lima, A. et al. Immunophenotypic features of tumor infiltrating lymphocytes
92
from mammary carcinomas in female dogs associated with prognostic factors and
survival rates. BMC Cancer 10, 256 (2010).
37.
Saeki, K. et al. Significance of tumor-infiltrating immune cells in spontaneous
canine mammary gland tumor: 140 cases. J. Vet. Med. Sci. 74, 227–230 (2012).
38.
Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).
39.
Migliorini, D., Mason, N. J. & Posey, A. D. Keeping the Engine Running: The
Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development.
ILAR Journal 59, 276–285 (2018).
40.
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the
current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).
41.
Milone, M. C. & Bhoj, V. G. The Pharmacology of T Cell Therapies. Mol. Ther.
Methods Clin. Dev. 8, 210–221 (2018).
42.
Panjwani, M. K. et al. Feasibility and safety of RNA-transfected CD20-specific
chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol.
Ther. 24, 1602–1614 (2016).
43.
Panjwani, M. K. et al. Establishing a model system for evaluating CAR T cell
therapy using dogs with spontaneous diffuse large B cell lymphoma.
Oncoimmunology 9, 1676615 (2020).
93
44.
Mata, M. et al. Toward immunotherapy with redirected T cells in a large animal
model: Ex vivo activation, expansion, and genetic modification of canine T cells. J.
Immunother. 37, 407–415 (2014).
45.
Yin, Y. et al. Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFvBased CAR T Cells to Treat Murine and Canine Gliomas. Mol. Ther. Oncolytics 11,
20–38 (2018).
46.
Stock, S., Schmitt, M. & Sellner, L. Optimizing manufacturing protocols of chimeric
antigen receptor t cells for improved anticancer immunotherapy. Int. J. Mol. Sci. 20,
6223 (2019).
47.
Morgan, R. A. & Boyerinas, B. Genetic modification of T cells. Biomedicines 4, 9
(2016).
48.
Klebanoff, C. A., Rosenberg, S. A. & Restifo, N. P. Prospects for gene-engineered T
cell immunotherapy for solid cancers. Nat. Med. 22, 26-36 (2015).
49.
Suerth, J. D., Labenski, V. & Schambach, A. Alpharetroviral vectors: From a cancercausing agent to a useful tool for human gene therapy. Viruses 6, 4811–4838 (2014).
50.
Pear, W. S. et al. Efficient and rapid induction of a chronic myelogenous leukemialike myeloproliferative disease in mice receiving p210 bcr/abl-transduced bone
marrow. Blood 15, 3780-3792 (1998).
94
51.
Van Damme, A. et al. Efficient Lentiviral Transduction and Improved Engraftment
of Human Bone Marrow Mesenchymal Cells. Stem Cells 24, 896–907 (2006).
52.
Ling, C., Migita, M., Hayakawa, J. & Fukunaga, Y. Establishment of Modified
Retroviral Vector Targeting X-Linked Severe Combined Immunodeficiency. J.
Nippon Med. Sch. 71, 51-56 (2004).
53.
Sarracino, D. C. et al. Effects of vector backbone and pseudotype on lentiviral vectormediated gene transfer: Studies in infant ADA-Deficient mice and rhesus monkeys.
Mol. Ther. 22, 1803–1816 (2014).
54.
Marcucci, K. T. et al. Retroviral and Lentiviral Safety Analysis of Gene-Modified T
Cell Products and Infused HIV and Oncology Patients. Mol. Ther. 26, 269–279
(2018).
55.
Cesana, D. et al. Uncovering and dissecting the genotoxicity of self-inactivating
lentiviral vectors in vivo. Mol. Ther. 22, 774–785 (2014).
56.
Dull, T. et al. A third-generation lentivirus vector with a conditional packaging
system. J. Virol. 72, 8463-8471 (1998).
57.
Hacein-Bey-Abina, S. et al. A Modified γ-Retrovirus Vector for X-Linked Severe
Combined Immunodeficiency. N. Engl. J. Med. 371, 1407–1417 (2014).
58.
Cornetta, K. et al. Replication-competent lentivirus analysis of clinical grade vector
95
products. Mol. Ther. 19, 557–566 (2011).
59.
Sastry, L. & Cornetta, K. Detection of Replication Competent Retrovirus and
Lentivirus. Methods Mol. Biol. 506, 243-263 (2009).
60.
Bear, A. S. et al. Replication-competent retroviruses in gene-modified T cells used in
clinical trials: Is it time to revise the testing requirements? Mol. Ther. 20, 246–249
(2012).
61.
McGarrity, G. J. et al. Patient monitoring and follow-up in lentiviral clinical trials.
J. Gene Med. 15, 78–82 (2013).
62.
Hacein-Bey-Abina, S. et al. A Serious Adverse Event after Successful Gene Therapy
for X-Linked Severe Combined Immunodeficiency. N. Engl. J. Med. 348, 255-256
(2003).
63.
Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two
patients after gene therapy for SCID-X1. Science 302, 415-419 (2003)
64.
Braun, C. J. et al. Gene therapy for Wiskott-Aldrich Syndrome-Long-Term Efficacy
and Genotoxicity. Sci. Transl. Med. 6, 227 (2014)
65.
Ott, M. G. et al. Correction of X-linked chronic granulomatous disease by gene
therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
Nat. Med. 12, 401–409 (2006).
96
66.
Heilmann, R. M., Guard, M. M., Steiner, J. M., Suchodolski, J. S. & Unterer, S. Fecal
markers of inflammation, protein loss, and microbial changes in dogs with the acute
hemorrhagic diarrhea syndrome (AHDS). J. Vet. Emerg. Crit. Care (2017).
67.
Stein, S. et al. Genomic instability and myelodysplasia with monosomy 7 consequent
to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med.
16, 198–204 (2010).
68.
Food and Drug Administation Center. Guidance for industry: gene therapy clinical
trials – observing subjects for delayed adverse events. (2006).
https://www.ngvbcc.org/pdf/gtclin.pdf;jsessionid=64AFB5DB8805374241D9FFBBD0
137CCF
69.
Kambayashi, T. & Laufer, T. M. Atypical MHC class II-expressing antigenpresenting cells: Can anything replace a dendritic cell? Nat.Rev. Immunol. 14, 719–
730 (2014).
70.
Hünig, T., Beyersdorf, N. & Kerkau, T. CD28 co-stimulation in T-cell homeostasis: a
recent perspective. Immunotargets Ther. 4, 111-122 (2015).
71.
Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and coinhibition. Nat. Rev. Immunol. 13, 227–242 (2013).
72.
Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer.
97
Cell 168, 724–740 (2017).
73.
Weinkove, R., George, P., Dasyam, N. & McLellan, A. D. Selecting costimulatory
domains for chimeric antigen receptors: functional and clinical considerations. Clin.
Transl. Immunology 8, e1049 (2019).
74.
Van Der Stegen, S. J. C., Hamieh, M. & Sadelain, M. The pharmacology of secondgeneration chimeric antigen receptors. Nat. Rev. Drug Discov. 14, 499–509 (2015).
75.
Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB
costimulation. JCI insight 3, e96979 (2018).
76.
Kowolik, C. M. et al. CD28 costimulation provided through a CD19-specific chimeric
antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively
transferred T cells. Cancer Res. 66, 10995–11004 (2006).
77.
Savoldo, B. et al. CD28 costimulation improves expansion and persistence of
chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest.
121, 1822–1826 (2011).
78.
Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic
signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).
79.
Zhao, Z. et al. Structural design of engineered costimulation determines tumor
rejection kinetics and persistence of CAR T Cells. Cancer Cell 28, 415–428 (2015).
98
80.
Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction
domains mediate enhanced survival of T cells and increased antileukemic efficacy in
vivo. Mol. Ther. 17, 1453–1464 (2009).
81.
Turtle, C. J. et al. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B
cell ALL patients. J. Clin. Invest. 126, 2123-2138 (2016).
82.
Kawalekar, O. U. et al. Distinct Signaling of Coreceptors Regulates Specific
Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity
44, 380–390 (2016).
83.
Guedan, S. et al. ICOS-based chimeric antigen receptors program bipolar TH17/ TH1
cells. Blood 124, 1070–1080 (2014).
84.
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large
B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
85.
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large Bcell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
86.
Abbott, R. C., Cross, R. S. & Jenkins, M. R. Finding the keys to the CAR: Identifying
novel target antigens for t cell redirection immunotherapies. Int. J. Mol. Sci. 21, 515
(2020).
87.
Casalini, P., Iorio, M. V., Galmozzi, E. & Ménard, S. Role of HER receptors family in
99
development and differentiation. J. Cell Physiol. 200, 343-350 (2004).
88.
Moasser, M. M. The oncogene HER2: Its signaling and transforming functions and
its role in human cancer pathogenesis. Oncogene 26, 6469-6487 (2007).
89.
Luo, H., Xu, X., Ye, M., Sheng, B. & Zhu, X. The prognostic value of HER2 in ovarian
cancer: A meta-analysis of observational studies. PLoS One 13, e0191972 (2018).
90.
Ménard, S., Fortis, S., Castiglioni, F., Agresti, R. & Balsari, A. HER2 as a Prognostic
Factor in Breast Cancer. Oncology 61, 67–72 (2001).
91.
Shao, X. et al. Correlation of Gli1 and HER2 expression in gastric cancer:
Identification of novel target. Sci. Rep. 8, 397 (2018).
92.
Suzuki, M. et al. HER2 gene mutations in non-small cell lung carcinomas:
Concurrence with her2 gene amplification and her2 protein expression and
phosphorylation. Lung Cancer 87, 14–22 (2015).
93.
Dai, Y.-J. et al. Concomitant high expression of ERα36, EGFR and HER2 is
associated with aggressive behaviors of papillary thyroid carcinomas. Sci. Rep. 7,
12279 (2017).
94.
English, D. P., Roque, D. M. & Santin, A. D. HER2 expression beyond breast cancer:
Therapeutic implications for gynecologic malignancies. Mol. Diagn. Ther. 17, 85-99
(2013).
100
95.
Flint, A. F. et al. Overexpression of the erbB-2 proto-oncogene in canine
osteosarcoma cell lines and tumors. Vet. Pathol. 41, 291-296 (2004).
96.
Gama, A., Alves, A. & Schmitt, F. Identification of molecular phenotypes in canine
mammary carcinomas with clinical implications: Application of the human
classification. Virchows Arch. 453, 123-132 (2008).
97.
Millanta, F. et al. Overexpression of HER-2 via immunohistochemistry in canine
urinary bladder transitional cell carcinoma -A marker of malignancy and possible
therapeutic target. Vet. Comp. Oncol. 16, 297-300 (2018).
98.
Vogel, C. L. & Franco, S. X. Clinical experience with trastuzumab (Herceptin).
Breast J. 9, 452–462 (2003).
99.
Awada, G., Gombos, A., Aftimos, P. & Awada, A. Emerging drugs targeting human
epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. Expert
Opin. Emerg. Drugs 21, 91-101 (2016).
100.
Hurvitz, S. A. & Kakkar, R. Role of lapatinib alone or in combination in the
treatment of HER2-positive breast cancer. Breast Cancer 4, 35-51 (2012).
101.
Mason, N. J. et al. Immunotherapy with a HER2-Targeting listeria induces HER2Specific immunity and demonstrates potential therapeutic effects in a phase I trial
in canine osteosarcoma. Clin. Cancer Res. 22, 4380-4390 (2016).
101
102.
Sakai, K. et al. Anti-tumor effect of lapatinib in canine transitional cell carcinoma
cell lines. Vet. Comp. Oncol. 16, 642-649 (2018).
103.
Perez, E. A., Cortés, J., Gonzalez-Angulo, A. M. & Bartlett, J. M. S. HER2 testing:
Current status and future directions. Cancer Treat. Rev. 40, 276-284 (2014).
104.
Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2
testing in breast cancer: american Society of Clinical Oncology/College of American
Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997-4013 (2013).
105.
Singer, J. et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine
cancer are susceptible to cetuximab and trastuzumab targeting. Mol. Immunol. 50,
200-209 (2012).
106.
Mar, N., Vredenburgh, J. J. & Wasser, J. S. Targeting HER2 in the treatment of
non-small cell lung cancer. Lung Cancer 87, 220–225 (2015).
107.
Liu, X., Zhang, N. & Shi, H. Driving better and safer HER2-specific CARs for cancer
therapy. Oncotarget 8, 62730-62741 (2017).
108.
Sakai, K. et al. Anti-tumour effect of lapatinib in canine transitional cell carcinoma
cell lines.Vet. Comp. Oncol. 16, 642-649 (2018).
109.
Lorch, G. et al. Identification of frequent activating HER2 mutations in primary
canine pulmonary adenocarcinoma. Clin. Cancer Res. 25, 5866-5877 (2019)
102
110.
Mata, M. et al. Towards immunotherapy with redirected T cells in a large animal
model: Ex vivo activation, expansion, and genetic modification of canine T cells. J.
Immunother. 37, 407–415 (2014).
111.
Morgan, R. A. et al. Case report of a serious adverse event following the
administration of t cells transduced with a chimeric antigen receptor recognizing
ERBB2. Mol. Ther. 18, 843–851 (2010).
112.
Ordóñez, N. G. Podoplanin: A novel diagnostic immunohistochemical marker. Adv.
Anat. Pathol. 13, 83-88 (2006).
113.
Kato, Y. et al. Molecular analysis of the pathophysiological binding of the platelet
aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Cancer Sci. 99, 54-61 (2008).
114.
Schacht, V. et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type
transmembrane glycoprotein, in human squamous cell carcinomas and germ cell
tumors. Am. J. Pathol. 99, 54-61 (2005).
115.
Ariizumi, T. et al. Expression of podoplanin in human bone and bone tumors: New
marker of osteogenic and chondrogenic bone tumors. Pathol. Int. 60, 193-202 (2010).
116.
Mishima, K. et al. Podoplanin expression in primary central nervous system germ
cell tumors: A useful histological marker for the diagnosis of germinoma. Acta
103
Neuropathol. 111, 563-568 (2006).
117.
Kan, S. et al. Podoplanin expression in cancer-associated fibroblasts predicts
aggressive behavior in melanoma. J. Cutan. Pathol. 41, 561-567 (2014).
118.
Kawase, A. et al. Podoplanin expression by cancer associated fibroblasts predicts
poor prognosis of lung adenocarcinoma. Int. J. Cancer 123, 1053-1059 (2008)
119.
Kitano, H. et al. Podoplanin expression in cancerous stroma induces
lymphangiogenesis and predicts lymphatic spread and patient survival. Arch.
Pathol. Lab. Med. 134, 1520-1527 (2010).
120.
Neri, S. et al. Podoplanin-expressing cancer-associated fibroblasts lead and enhance
the local invasion of cancer cells in lung adenocarcinoma. Int. J. Cancer (2015).
121.
Cueni, L. N. et al. Tumor lymphangiogenesis and metastasis to lymph nodes induced
by cancer cell expression of podoplanin. Am. J. Pathol. 137, 784-796 (2010).
122.
Kunita, A. et al. The platelet aggregation-inducing factor aggrus/podoplanin
promotes pulmonary metastasis. Am. J. Pathol. 170, 1337-1347 (2007).
123.
Wicki, A. et al. Tumor invasion in the absence of epithelial-mesenchymal transition:
Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9, 261-272
(2006).
124.
Bertozzi, C. C. et al. Platelets regulate lymphatic vascular development through
104
CLEC-2-SLP-76 signaling. Blood 116, 661-670 (2010).
125.
Tuccillo, F. M. et al. Aberrant glycosylation as biomarker for cancer: Focus on CD43.
Biomed Res. Int. 2014, 742831 (2014).
126.
Kato, Y. & Kato Kaneko, M. A Cancer-specific Monoclonal Antibody Recognizes the
Aberrantly Glycosylated Podoplanin. Sci. Rep. 4, 5924 (2014)
127.
Chang, Y. W., Yamada, S., Kaneko, M. K. & Kato, Y. Epitope Mapping of Monoclonal
Antibody PMab-38 Against Dog Podoplanin. Monoclon. Antib. Immunodiagn.
Immunother. 36, 291-295 (2017).
128.
Honma R, Kaneko MK, Ogasawara S, Fujii Y, Konnai S, Takagi M, K. Y. Specific
detection of dog podoplanin expressed in renal glomerulus by a novel monoclonal
antibody PMab-38 in immunohistochemistry. Monolon. Antib. Immunodiagn.
Immunother. 35, 212-216 (2016)
129.
Ogasawara, S. et al. Podoplanin Expression in Canine Melanoma. Monoclon. Antib.
Immunodiagn. Immunother. 35, 304–306 (2016).
130.
Uchida, M. et al. Apoptosis inhibitor of macrophage (AIM) reduces cell number in
canine histiocytic sarcoma cell lines. J. Vet. Med. Sci. 78, 1515–1520 (2016).
131.
Greenberger, J. S. et al. Cancer-associated fibroblasts from lung tumors maintain
their immunosuppressive abilities after high-dose irradiation. Front. Oncol. 5, 87
105
(2015).
132.
Ohashi, E. et al. Effect of retinoids on growth inhibition of two canine melanoma cell
lines. J. Vet. Med. Sci. 63, 83-86 (2001).
133.
Rolih, V. et al. CSPG4: A prototype oncoantigen for translational immunotherapy
studies. J. Transl. Med. 15, 151 (2017).
134.
Inoue, K. et al. Establishment and characterization of four canine melanoma cell
lines. J. Vet. Med. Sci 66, 1437-1440 (2004).
135.
Yamada, S. et al. Epitope mapping of monoclonal antibody PMab-48 against dog
podoplanin. Monoclon. Antib. Immunodiagn. Immunother. 37, 162–165 (2018).
136.
Yamada, S., Itai, S., Kaneko, M. K. & Kato, Y. PMab-48 Recognizes Dog Podoplanin
of Lymphatic Endothelial Cells. Monoclon. Antib. Immunodiagn. Immunother. 37,
63–66 (2018).
137.
Xing, F., Saidou, J. & Watabe, K. Cancer associated fibroblasts (CAFs) in tumor
microenvironment. Front. Biosci. 15, 166-179 (2010)
138.
Yoshimoto, S., Hoshino, Y., Izumi, Y. & Takagi, S. α-Smooth muscle actin expression
in cancer- associated fibroblasts in canine epithelial tumors. Jpn. J. Vet. Res. 65,
135–144 (2017).
139.
Ogasawara, S. et al. Podoplanin expression in canine melanoma. Monoclon. Antib.
106
Immunodiagn. Immunother. 35, 304-306 (2016).
140.
Kaneko, M. K. et al. PMab-38 Recognizes canine podoplanin of squamous cell
carcinomas. Monoclon. Antib. Immunodiagn. Immunother. 35, 263-266 (2016).
141.
Król, M. et al. The gene expression profiles of canine mammary cancer cells grown
with carcinoma-associated fibroblasts (CAFs) as a co-culture in vitro. BMC Vet. Res.
8, 35 (2012).
107
...
論文の公開元へ
